title: [A multicenter randomized phase III trial of domestic product of rmhTNF in the treatment of non-small cell lung cancer].
abstract: BACKGROUND
  To evaluate and compare the effects and toxicity of the domestic product of recombinant mutant human tumor necrosis factor (rmhTNF) combined with chemotherapy and chemotherapy alone in the treatment of patients with non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Two hundred patients with NSCLC in multicenter were randomly devided into trial group (150 cases) and control group (50 cases). Chemotherapy with CAP regimen was given to the patients. Meanwhile, rmhTNF injection of 4×10⁶U/m² was also given from the 1st to 7th days, the 11th to 17th days on the chemotherapy cycle in the trial group. The control patients received chemotherapy alone. Twenty-one days were as a cycle, 2 cycles were given to each patient. The chemotherapeutic effects and toxicity were observed and compared between the two groups after the therapy.
  
  
  RESULTS
  of the 200 patients, 5 cases in the trial group and 3 cases in the control group were out of the trial because of economy. The other 192 cases (145 cases in the trial group and 47 cases in the control group) could be analyzed and evaluated the clinical effects and toxicity. The response rate of chemotherapy was 46.90% (68/145) in the trial group and 17.02% (8/47) in the control group respectively ( P =0.001). The KPS scores was 86.02±9.74 in the trial group, and 80.14±9.10 in the control group ( P =0.025). No significant difference of degree III+IV toxicity was observed between the two groups ( P > 0.05). The side effects related to rmhTNF included slight fever, cold-like symptoms, pain and red and swelling in the injection site. All of them were mild and didn't need any treatment and disappeared after the therapy. There were no severe abnormality of liver and kidney function and ECG in both groups.
  
  
  CONCLUSIONS
  The results demonstrate that the effects of domestic rmhTNF combined with chemotherapy are remarkably higher than that of chemotherapy alone in the treatment of NSCLC. rmhTNF can increase the sensitivity to chemotherapy and improve the quality of life of the patients with slight toxicity. Hence rmhTNF is worth expanding clinical use.
authors.affiliation: Cancer Center, West China Hopital, Sichuan University, Chengdu, Sichuan 610041, P.R.China.
authors.forename: Qinghua
authors.initials: Q
authors.lastname: Zhou
authors.forename: Xi
authors.initials: X
authors.lastname: Yan
authors.forename: Li
authors.initials: L
authors.lastname: Ren
authors.forename: Lu
authors.initials: L
authors.lastname: Li
authors.forename: Meng
authors.initials: M
authors.lastname: Qiu
authors.forename: Yuqiong
authors.initials: Y
authors.lastname: Yang
authors.forename: Deyun
authors.initials: D
authors.lastname: Luo
authors.forename: Wenxia
authors.initials: W
authors.lastname: Huang
authors.forename: Luming
authors.initials: L
authors.lastname: Liu
authors.forename: Zhen
authors.initials: Z
authors.lastname: Chen
authors.forename: Zhiqiang
authors.initials: Z
authors.lastname: Meng
authors.forename: Yajie
authors.initials: Y
authors.lastname: Wang
authors.forename: Qiang
authors.initials: Q
authors.lastname: Fu
authors.forename: Yang
authors.initials: Y
authors.lastname: Xu
authors.forename: Linjun
authors.initials: L
authors.lastname: Yang
authors.forename: Mingzhong
authors.initials: M
authors.lastname: Li
authors.forename: Enxiao
authors.initials: E
authors.lastname: Li
authors.forename: Yi
authors.initials: Y
authors.lastname: Li
authors.forename: Yu
authors.initials: Y
authors.lastname: Yao
authors.forename: Xiangfu
authors.initials: X
authors.lastname: Zhang
authors.forename: Xing
authors.initials: X
authors.lastname: Liu
authors.forename: Huishan
authors.initials: H
authors.lastname: Lu
authors.forename: Maohong
authors.initials: M
authors.lastname: Zhang
authors.forename: Xiuwen
authors.initials: X
authors.lastname: Wang
authors.forename: Xuejun
authors.initials: X
authors.lastname: Yu
authors.forename: Fengzhan
authors.initials: F
authors.lastname: Qin
authors.forename: Rongsheng
authors.initials: R
authors.lastname: Zheng
authors.forename: Yuqing
authors.initials: Y
authors.lastname: Chen
authors.forename: Minghong
authors.initials: M
authors.lastname: Bi